CorVent Medical, Santa Clara, Calif., has received CE Mark approval and is ready to launch commercial use of its Respond-19 Ventilator in Europe. The novel system is designed for easy-to-use, flexible expansion of critical care ventilation capacity to allow hospitals to improve treatment of critically ill patients suffering from acute respiratory distress syndrome. Optimized for day-to-day clinical use and overflow ventilation needs, the system provides invasive and non-invasive respiratory support at a lower cost of ownership without the traditional requirements for costly service or maintenance plans.
The ICU-quality system includes mandatory, assist, and spontaneous ventilation modes along with built-in safeguards to meet individual patients’ needs. The streamlined, lightweight design simplifies training, ensures compatibility with all low-flow oxygen sources, and allows for easy movement within the hospital. In addition, the system filters out 99.9% of viral pathogens using antiviral safeguards to protect both patients and staff.
Optimized for a low cost of ownership, the system is ready to use out of the box from long-term storage without ongoing service contracts or costly maintenance. The Respond-19 Ventilator is ideal for day-to-day clinical use or overflow ventilation needs.
To support the company’s growth, CorVent also announced the expansion of its senior management team and welcomed seasoned medtech executive Travis Murphy as chief financial officer (CFO). “A hospital’s ventilation needs have shifted in recent years; they require flexibility to respond to changes in demand without the high cost of ongoing ownership. Today’s systems must meet the rigorous mechanical ventilation requirements of the ICU but also be easy to use and deployed rapidly to expand critical care capacity when time is limited,” says Richard S. Walsh, CEO of CorVent Medical.
“Our experienced team has made meaningful inroads into the respiratory market with the Respond-19 Ventilator in a short time and the market’s response has been very positive. Bringing Travis Murphy on as our company’s CFO will be invaluable to expanding our commercialization efforts,” Walsh adds.
The Respond-19 Ventilator was recently recognized as a 2021 Silver Winner of the Medical Design Excellence Award from Medical Device and Diagnostic Industry in the category of ER and OR Tools, Equipment, and Supplies.
In late 2020, CorVent received emergency use authorization (EUA) from the U.S. FDA for the Respond-19 Ventilator and announced a U.S. distribution partnership with Siemens Healthineers. The company anticipates full FDA clearance of the system in 2021.
Featured image: CorVent Medical has received CE Mark approval and is ready to launch commercial use of its Respond-19 Ventilator in Europe.